Irosustat: A first-generation steroid sulfatase inhibitor in breast cancer

Expert Review of Anticancer Therapy

Volumn 11, Issue 2, 2011, Pages 179-183

  Palmieri, Carlo ^a   Januszewski, Adam ^a   Stanway, Susie ^a   Coombes, R Charles ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

breast cancer; endocrine therapy; inhibition; irosustat; steroid sulfatase

Indexed keywords

667 COUMATE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; BN 83495; EMOLLIENT AGENT; IROSUSTAT; STERYL SULFATASE; STX 64; TAMOXIFEN; UNCLASSIFIED DRUG;

ANOREXIA; ARTHRALGIA; ARTICLE; BLOOD TOXICITY; BREAST CANCER; CANCER REGRESSION; DRUG DOSE ESCALATION; DRUG INHIBITION; DRUG SAFETY; DRUG TOLERABILITY; DRY SKIN; FATIGUE; HEADACHE; HOT FLUSH; HUMAN; MOOD DISORDER; NAUSEA; TASTE DISORDER; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; CLINICAL TRIALS, PHASE II AS TOPIC; DEHYDROEPIANDROSTERONE SULFATE; ESTRADIOL; ESTRONE; FEMALE; HUMANS; NEOPLASMS, HORMONE-DEPENDENT; STERYL-SULFATASE; SULFONIC ACIDS; TAMOXIFEN;

EID: 79952145164     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.10.201     Document Type: Article

References (19)

1. Coombes RC, Hall E, Gibson LJ et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N. Engl. J. Med. 350, 1081-1092 (2004).
2. Hobkirk R. Steroid sulfation current concepts. Trends Endocrinol. Metab. 4, 69-74 (1993).
3. Ruder HJ, Loriaux L, Lipsett MB. Estrone sulfate: production rate and metabolism in man. J. Clin. Invest. 51, 1020-1033 (1972).
4. Miyoshi Y, Ando A, Shiba E et al. Involvement of up-regulation of 17β-hydroxysteroid dehydrogenase type 1 in maintenance of intratumoral high estradiol levels in postmenopausal breast cancers. Int. J. Cancer 94, 685-689 (2001).
5. Poulin R, Labrie F. Stimulation of cell proliferation and estrogenic response by adrenal C19-δ 5-steroids in ZR-75-71 human breast cancer cell line. Cancer Res. 46, 4933-4937 (1986).
6. Dauvois S, Labrie F. Androstenedione and androst-5-ene-3β, 17β-diolstimulate DMBA-aromatized rat mammary tumours: role of aromatase. Breast Cancer Res. Treat. 13, 61-69 (1989).
7. Billich A, Nussbaumer P, Lehr P. Stimulation of MCF-7 breast cancer cell proliferation by estrone sulphate and dehydroepiandrosterone sulfate: inhibition by novel non-steroidal sulfatase inhibitors. J. Steroid Biochem. Mol. Biol. 73, 225-235 (2000).
8. Pizzagalli F, Varga Z, Huber RD, Folkers G, Meier PJ, St-Pierre MV. Identification of steroid sulfate transport processes in the human mammary gland. J. Clin. Endocrinol. Metab. 88, 3902-3912 (2003).
9. Utsumi T, Yoshimura N, Takeuchi S, Maruta M, Maeda K, Harada N. Elevated steroid sulfatase expression in breast cancer. J. Steroid Biochem. Mol. Biol. 73, 141-145 (2000). Revealed a higher expression of steroid sulfatase in malignant breast tissue compared with normal breast tissue.
10. Utsumi T, Yoshimura N, Takeuchi S et al. Steroid sulfatase expression is an independent predictor of recurrence in human breast cancer. Cancer Res. 59, 377-381 (1999). Steroid sulfatase mRNA in breast cancer was shown to be significantly associated with an increased risk of recurrence.
11. Suzuki T, Nakata T, Miki Y et al. Estrogen sulfotransferase and steroid sulfatase in human breast carcinoma. Cancer Res. 63, 2762-2770 (2003). Revealed the prognostic importance of steroid sulfatase and estrogen sulfotransferase by immunohistochemistry.
12. Falany JL, Falany CN. Regulation of estrogen activity by sulfation in human MCF-7 breast cancer cells. Oncol. Res. 9, 589-596 (1997).
13. Qian Y, Deng C, Song WC. Expression of estrogen sulfotransferase in MCF-7 cells by cDNA transfection suppresses the estrogen response: potential role of the enzyme in regulating estrogen-dependent growth of breast epithelial cells. J. Pharmacol. Exp. Ther. 286, 555-560 (1998).
14. Morris KT, Toth-Fejel S, Schmidt J, Fletcher WS, Pommier RF. High dehydroepiandrosterone-sulphate predicts breast cancer progression during new aromatase inhibitor therapy and stimulates breast cancer cell growth in tissue culture: a new role for adrenalectomy. Surgery 130, 947-953 (2001). Discusses the potential role of dehydroepiandrosterone sulfate in breast cancer progression on aromatase inhibitors (AIs).
15. Chanplakorn N, Chanplakorn P, Suzuki T et al. Increased estrogen sulfatase (STS) and 17β-hydroxysteroid dehydrogenase type 1(17β-HSD1) following neoadjuvant aromatase inhibitor therapy in breast cancer patients. Breast Cancer Res. Treat. 120, 639-648 (2010). This neoadjuvant study demonstrated the upregulation of steroid sulfatase in tumors treated with an AI, which could serve as a potential compensatory mechanism to the depletion of intratrumoral estrogen, and therefore a mechanism of resistance to AI treatment.
16. Malini B, Purohit A, Ganeshapillai D, Woo LW, Potter BV, Reed MJ. Inhibition of steroid sulfatase activity by tricyclic coumarin sulphamates. J. Steroid Biochem. Mol. Biol. 75, 253-258 (2000). Describes the synthesis and activity of a series of tricyclic 4-methylcoumarin-7-O-sulphamate (Coumate; later called irosustat). 667 Coumate (later called STX64) is the compound that subsequently entered a Phase I study and was later renamed irosustat.
17. Purohit A, Woo LW, Potter BV, Reed MJ. In vivo inhibition of estrone sulfatase activity and growth of nitromethylurea-aromatized mammary tumours by 667 COUMATE. Cancer Res. 60, 3394-3396 (2000). Demonstrated that 667 Coumate caused the regression of estrone sulfate-stimulated tumor growth in a dose-dependent manner.
18. Stanway SJ, Purohit A, Woo LW et al. Phase I Study of STX 64 (667 Coumate) in breast cancer patients: the first study of a steroid sulfatase inhibitor. Clin. Cancer Res. 12, 1585-1592 (2006). First Phase I study of irosustat that revealed the potency of this agent as a sulfatase inhibitor and unexpectedly showed a decrease in androstenedione, revealing the importance of peripheral production.
19. 18FDG-PET scans.